Roche reveals first data with Carmot-sourced oral GLP-1 drug Roche has reported early-stage clinical data with an oral GLP-1 agonist acquired as part of its $3.1 billion takeover of Carmot Therapeutics as it tries to catch up with the leaders in the fast-growing category
El-Heis S, DAngelo S, Curtis EM, Healy E, Moon RJ, Crozier SR, Inskip H, Cooper C, Harvey NC, Godfrey KM
And unlike direct antioxidant supplements (e.g., vitamin C or E), which often fail in clinical trials due to poor bioavailability or paradoxical pro-oxidant effects, Epitalon works endogenously, stimulating the body's systems with surgical precision
Shigenaga M K, Hagen T M,et al
This property is directly related to its gastric origin: it resists enzymatic degradation in the stomach, which opens the door to oral administration a considerable advantage over other peptides that strictly require injection
10.1111/dom.13538 3 BuckleyS